Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Whole Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Rectal Adenocarcinoma
NCT02319304Phase 2Terminated
- Sponsor
- University of Maryland, Baltimore
- Start
- Mar 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FOLFOX in rectal adenocarcinoma, sponsored by University of Maryland, Baltimore. Primary endpoint: Overall Survival Rate at 1 year. Started Mar 2015; status: terminated.
02
Drugs
FOLFOX
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT02319304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02319304.